3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Muscle Invasive Bladder Cancer
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
tislelizumab
2
Cystectomy
2
vistusertib
1
toripalimab
1
olaparib
1
liposomal doxorubicin
1
durvalumab
1
disitamab vedotin
1
danvatirsen
1
adavosertib
1
Surgical Procedures, Operative
1
Rutin
1
Radiation
1
RC48 antibody
1
Neoadjuvant Therapy
1
Gemcitabine
1
Cisplatin
1
Chemoradiotherapy
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Muscle Invasive Bladder Cancer
×
adavosertib
×
Genitourinary
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled